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Abstract
Background: Infections with influenza A virus cannot be clinically differentiated from infections caused by influenza
B virus or other respiratory viruses. Additionally, although antiviral treatment is available for influenza A virus, it is
not effective for the other viruses and must be initiated early in the course of disease for it to be effective. For
these reasons, there is a need for a rapid, accurate diagnostic test for use in physicians’ offices at the time patients
are seen. We report the first field performance of BD Veritor™ System for Rapid Detection of Flu A + B test compared
to real time PCR. The performance of this test was compared to real time PCR performed in the Istanbul University
Influenza Reference Laboratory.
Method: A single-blinded cross sectional study was conducted in nine different family medicine centers in Istanbul,
Turkey between 01 November 2014 and 01 May 2015. For every patient, two specimens were collected, one for real
time PCR and one for the Veritor test. Specimens for the Veritor test were immediately tested at the participating
clinic according to the manufacturer’s instructions. The specimens for real time PCR were transferred to the reference
laboratory.
Results: A total of 238 persons were included in the study: 72 (30 %) of the patients included in the study were
below 19 years old and accepted as childhood group. Mean age of adults was 42.4 and children 10.2 years. A
total of 122 patients out of 238 were positive for influenza. The clinical sensitivity and specificity of the Veritor
test in all age groups was determined to be 80 and 94 %, respectively. Positive predictive value was 93 % and the
negative one was 81 %.
Conclusion: Field performance of the rapid influenza test was high and found to be useful with respect to
rational antiviral use, avoiding unnecessary antibiotic usage and the management of cases by the family
physicians.
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Background
Influenza is a contagious disease associated with sea-
sonal outbreaks and significant morbidity and mortality
in high risk groups [1–3]. Although the gold standard
for diagnosis of influenza is virus isolation, immunoas-
says and real time nucleic acid amplification tests are
used most commonly for laboratory diagnosis [4]. In
practice, most of the cases are diagnosed clinically
because in the primary healthcare services where
patients most frequently present, there are no laboratory
resources that can confirm the diagnosis and forwarding
samples to more advanced centers causes unacceptable
delays.
Clinical differentiation of influenza A virus from infec-
tions caused by influenza B virus and the other viruses is
unreliable. On the other hand, effective antiviral treat-
ment is only available for influenza A virus infections
and must be administered early in the course of disease
to be effective [5, 6].
Point-of-care tests are available for primary healthcare
services; however, the clinical sensitivity and specificity
of commercial rapid tests vary significantly. The preva-
lence of the disease is also important in assessing its
positive and negative predictive value. During peak influ-
enza activity, a positive test result has the highest prob-
ability of indicating the presence of infection, but a
negative result does not exclude influenza infection due
to low negative predictive value. In contrast, during low
influenza activity such as during the warm months of
the year a positive result has the lowest probability of
predicting disease [7]. Rapid influenza test results are
also influenced by patient age, duration of illness before
specimen collection, specimen type, transport and stor-
age conditions, and the type of influenza virus [8, 9].
Historically, rapid influenza virus antigen diagnostic
tests (RIDTs) were simple to perform but were insensi-
tive, particularly for recently introduced strains of influ-
enza A virus and influenza B virus. In contrast, the more
recently introduced digital immunoassays (DIAs) have
improved analytical performance [10, 11]. The DIAs are
instrument-based line immunoassays with increased
clinical sensitivity and objective digital interpretation
of the test results eliminating the subjectivity of read-
ing the test results. Currently, two DIAs are FDA-
approved and CLIA waived, BD Veritor System and
Quidel Sofia. Although these tests are less sensitive
than nucleic acid amplification tests (e.g., real time-
polymerase chain reaction; RT-PCR), their perform-
ance is generally equivalent to RT-PCR early in the
course of disease when virus titers are highest and
antiviral treatment is most effective [12, 13]. In spite
of the limitations of the tests, rapid tests can be an
important option with respect to clinical decisions
and disease management by the primer care [14, 15].
The use of these rapid diagnostic tests can also pro-
vide an early warning of influenza virus infections in
a community [16]. For these reasons, the World
Health Organization (WHO) has recomended the use
of rapid tests in clinical decision making processes
and early detection and control of outbreaks.
Because of most point-of-care tests are performed in
primary care settings, this study was performed to assess
the field performance of BD Veritor™ System for Rapid
Detection of Flu A + B test compared to RT-PCR.
Methods
This single-blinded cross sectional study was conducted
in nine different family medicine centers in Istanbul,
Turkey between 01 November 2014 and 01 May 2015.
Participants
In Istanbul, there are 15 family physicians taking part in
the National Influenza Sentinel Surveillance system and
sending the samples to the National Influenza Labora-
tory of the Istanbul University. Nine family physicians
participated to this study. Any patient who sought care
for an influenza-like illness (ILI) and gave consent was
accepted in the study. WHO criteria were used to define
an ILI diagnosis [17]. Each of the physicians received
training on the principles of the Veritor test, proper
methods for performing the test, and the appropriate
specimen collection technique.
The Public Health Institute of Turkey standardized
surveillance form was completed by the family physi-
cians for each patient and included questions regarding
demographic characteristics, chronic diseases, presumed
method of exposure to the respiratory virus, anti-
viral treatment, and the need for referral to hospital.
Specimen collection
Nasopharyngeal specimens were collected by the phy-
sicians at the time of the intial patient visit (typically
within 3 days of the onset of symptoms). Two speci-
mens were collected, from each patient: one for RT-
PCR and one for the Veritor test. Specimens for the
Veritor test were immediately tested at the participat-
ing clinic according to the manufacturer’s instruc-
tions. The samples for RT-PCR were taken with a
Virocult swab (Medical Wire Equipment CO, Ref No:
MW 950S, England) inserted into viral transport
media and stored at 4 °C for a maximum of 48 h
before transport to the reference lab [18].
BD veritor™ system for rapid detection of flu A + B
The BD Veritor™ System for Rapid Detection of Flu A +
B is a rapid digital chromatographic immunoassay for
the direct, qualitative detection of influenza A and B viral
nucleoprotein antigens from nasal and nasopharyngeal
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swabs of symptomatic patients. The BD Veritor System
for Rapid Detection of Flu A + B (also referred to as the
BD Veritor System and BD Veritor System Flu A + B)
differentiates influenza A and B viral antigens from a
processed sample using a single device. Each naso-
pharyngeal sample was transferred to a reagent tube,
mixed thoroughly, and three drops of the processed
sample was dispensed into the sample well of the BD
Veritor System Flu A + B test. After 10 min, the test
device was inserted into the BD Veritor System
reader, and test results (e.g., positive for Flu A, for
Flu B, or negative) were digitally displayed by the in-
strument within 10 s.
PCR testing
The swab samples were delivered to the Influenza Refer-
ence Laboratory in Istanbul University using courier sys-
tem accompanied by patient information form. After
checking suitability of samples and doing necessary
registration, the virocult was vortexed to homogenize
the specimen and then specimens were transferred to a
Cryo tube (Corning cryogenic vial 2.0 ml, Ref No:
CLS430659 SIGMA, England). Specimens were main-
tained at 4 °C if they were processed within 2 days of
collection or frozen at -20 °C or -80 °C if the delay was
for a longer period [18]. EZ1 Virus Mini Kit V 2.0 and
Advanced XL device (QIAGEN, Ref No: 955134,
Germany) was used for viral RNA extraction according
to the manufacture’s instructions. The Centers for Dis-
ease Control and Prevention (CDC) RT-PCR protocol
which was suggested was used. The primer-probe assays
belonged to ribonucleoprotein (RNaseP) gene region,
used as internal control, were provided by WHO. Amp-
lification process was performed in the LightCycler 480
II (Roche, Germany) using Real Time ready RNA Virus
Master (Light Cycler 480 RNA Master (Roche, Ref No:
05619416001, Germany) enzyme mixture. For each sam-
ple 5 μl RNA was added to a total 15 μl reaction mixture
(8.6 μl molecular grade water, 0.5 μl primer, 1 μl probe,
0.4 μl enzyme and 4 μl reaction buffer). Amplification con-
ditions were 8 min at 50 °C, 45 cycles of at 0.1 s at
95 °C + 20 s at 55 °C, + 0.1 s at 72 °C) X 45 cycle
and 30 s at 40 °C. The result were reported with the
analysis of amplification plot in the Light Cycler 480
II platform [19].
At the and of the study a depth interview with the physi-
cians included in the study has been done and recorded
and analyzed. The qestions were “How rapid test affected
your management of upper airway infections”. The re-
cordings were listened to, transcribed, and correlated with
the notes that interviewers had taken during the interview.
Each focus group transcript was read separately and dur-
ing a meeting to form a coding structure. Two
investigators read, identified, and assigned codes for the
major themes of the data.
Results
A total of 238 persons were included in the study: 135
women and 103 men (Table 1). A total of 30 % of the
patients were less than 19 years of age with the mean
age 10.2 years. The mean age of adults was 42.4 years
(range 19–84). The interval between onset of symptoms
and admission to family health centers was 2.2 days
(range 1–7 days) in adults and was 2.2 days (range 1–8
days) in children. There was one pregnant women, one
morbidly obese person and no immunosuppressive pa-
tient in the study group.
A total of 122 patients out of 238 were positive for
influenza by RT-PCR including 42 with influenza A
H1N1, 11 with influenza A H3N2, two with influenza A
undetermined strains, and 68 with influenza B. One
patient’s PCR test was positive for both influenza A and
B but the Verritor test was negative for both viruses.
The analytical performance of the Veritor Influenza A +
B rapid test is summarized in Table 2 compared with
influenza B virus infections. Overall clinical sensitivity
and specificity for all patient populations was 80 and
94 %, respectively, with higher clinical sensitivity re-
ported for patients with influenza A virus infections,
(82 % versus 74 %). The differences were not statistically
significant.
Six of nine physicians attended to the interview ses-
sion. The main themes that physicians have agreed are
given below:
Influences on management of upper airway infections:
Rapid test has increased the self confidence of physicians
since faciliated the definitive diagnosis. Rapid test has
also inceased their awareness of that the flu season has
begun. Also they expressed that it has also increased the
Table 1 Characteristics of the study group
Childhood
group
N = 72 (%)
Adulthood
group
N = 166 (%)
Whole
group
N = 238 (%)
Female 26 109 135 (56.7 %)
Male 46 57 103 (43.3 %)
Age 10.3 ± 4.7 42.5 ± 13.7 32.7 ± 18.9
Symptom-onset
interval (days)
2.8 ± 1.9 2.3 ± 1.5 2.3 ± 1.6
Seasonal Flu vaccine 2 (2.8 %) 11 (6.6 %) 13 (5.5 %)
Presence of chronica
diseases
2 (2.8 %) 19 (11.4 %) 21 (8.8 %)
aValid percent of chronic diseases; allergic rhinitis 4 %, asthma 1.6 %, diabetes
and hepatitis C 4 %, diabetes and hypertension 4 %, epilepsy 4 %,
hypothyroid 4 %, hypertension 1.2 %, hypertension and congestive cardiac
failure 4 %, chronic pulmoner diseases 4 %, chronic obstructive pulmoner
diseases 8 %, chronic obstructive pulmoner diseases and hypertension 4 %,
breast cancer 4 %, splenectomy 4 %.
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confidence of patients and had positive effect on doctor-
patient relationship. It also increased the examination
time due to the physicians spend more time for consult-
ation of preventive measures to be taken and acknow-
ledgement of about the disease. It had not specific effect
on reference of secondary-tertiary care.
Influences on prescription: In general rapid test has
not changed the prescriptions. In few patients physicians
expressed that they had oppurtunity to convince patients
to not to use antibiotics. Also, it has faciliated to decide
prescribing antivirals.
In general since PCR test results have arrived in one
or two days, a tool supporting the immediate diagnosis
has positively effected the management and follow-up of
the patients admitted with flu symptoms. The overall
feedback from the family physicians was positive during
the physician group interviews after the study. Although
the family physicians expressed that their prescriptions
were not significantly influenced by the test results, the
test facilitated the decision to prescribe or not to pre-
scribe antibiotics and was also useful in reasurring their
patients not to use antibiotics. In general, the greatest
benefit of the test was useful for explaining the disease
and routes of contamination to the patients, and the
risks of potential complications associated with influenza
virus infections.
Discussion
The historical gold standard for detection of influenza
virus is virus isolation in cell culture. In practice, virus
isolation has been replaced by RT-PCR in most reference
laboratories [20]; however, RT-PCR tests are not per-
formed in the primary healthcare setting because of the
technical complexity of these tests. Additionally, because
of the delays associated with transport of specimens to
reference labs and the time required for performance of
RT-PCR tests and receipt of results from reference la-
boratories is typically too slow to be useful for the
clinical management of patients [21]. This delay usually
has a negative impact on appropriate antiviral treatment
and prevention of transmission, particularly in individ-
uals living with others who are in high risk groups [6,
22, 23]. A rapid accurate test that can be performed in
the primary care setting would facilitate the manage-
ment of suspected influenza virus infections.
Rapid influenza diagnostic tests (RIDTs) have historic-
ally been too insensitive to be used reliably for patient
care; however, the newly introduced DIAs are reported
to have superior performance [10, 11, 24, 25]. These
studies have been performed in well-controlled, cen-
tralized laboratories or during clinical trials, so the per-
formance may not reflect the results obtained in busy
primary care facilities. For that reason, we performed
this multisite study. In this study in a primary care set-
ting, the BD Veritor System Flu A + B test had excellent
clinical sensitivity and specificity in all age groups (80
and 94 %, respectively) and the positive and negative
predictive values were 93 and 81 %, respectively, in a
population with a 51 % prevalence of disease.
In a study comparing three different rapid antigen
tests, BD Veritor System Influenza A + B test was found
to have a good performance. In a study conducted in
children under 18 years of age, positive predictive value
was found to be 91.8 % and negative predictive value was
98.4 % [25]. In another study comparing three different
rapid antigen tests, it was concluded that the Veritor
Influenza A + B test was superior to the other tests [26].
In the influenza season of the 2014–2015 when the
study was conducted, initial cases were seen in January
and the seasonal outbreak began in February and contin-
ued until the middle of April. We believe the incidence
of influenza infections in the study population reflected
disease in the general population. In The National Influ-
enza Reference Laboratory of Istanbul University re-
ported 55.1 % of 2068 patients were infected with
influenza B, 35.4 % with influenza A H1N1, and 9.4 %
Table 2 Clinical sensitivity and specificity, predictive values of BD Veritor System for Flu AB test
RT-PCR




Influenza (A + B) in the whole study population 78 (95/122) 93 (108/116) 92 (96/104) 81 (108/134)
Influenza (A + B) in children (age < 19 years) 76 (28/37) 94 (33/35) 97 (29/31) 80 (33/41)
Influenza (A + B) in adults (age = or >19 years) 79 (67/85) 93 (75/81) 92 (67/73) 81 (75/93)
Influenza A in the whole study population (n = 55) 82 (45/55) 97 (177/183) 88 (45/51) 95 (177/187)
Influenza A in children (age < 19 years) 87 (14/16) 96 (54/56) 87 (14/16) 96 (54/56)
Influenza A in adult (= or >19 years) 79 (31/39) 97 (123/127) 89 (31/35) 94 (123/131)
Influenza B in the whole study population 74 (50/68) 99 (168/170) 96 (50/52) 90 (168/186)
Influenza B in children (age < 19 years) 67 (14/21) 100 (51/51) 100 (14/14) 88 (51/58)
Influenza B in adults (age = or >19 years) 77 (36/47) 97 (117/119) 95 (36/38) 91 (117/128)
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with influenza A H3N2, similar to the distribution ob-
served in this study. It is known that the positive and
negative predictive values of diagnostics are affected by
the prevalence of disease [7]. In this study, the positive
predictive values for influenza B was higher (95 % versus
100 %) and the negative predictive values for influenza A
was higher (94 % versus 96 %). The test detected most
of the influenza B cases immediately. This result can be
explained by the fact that cases in seasonal outbreaks are
predominantly influenza B cases.
Rapid tests reduce additional test requests in both pri-
mary healthcare and emergency services, increase the rate
of rational antiviral treatment, decrease the rate of in-
appropriate antibiotic use and impact clinical decision
making in general in a positive manner [27–30]. The goal
of this study was to assess the performance of the rapid
Veritor Flu A + B test. Because performance in a primary
care facility was unknown, no effort was made to measure
the influence of the test result on patient management.
Clearly this would be an important future study.
However, the overall feedback from the family physi-
cians was positive during the physician group interviews
after the study was completed. The family physicians test
results, the test facilitated the decision antiviral and use-
ful in reassuring the patients not to use antibiotics when
a negative result was obtained. Additionally the physi-
cians felt test was useful for initiating a discussion about
influenza virus infections, routes of exposure and trans-
mission, and the risks of potential complications associ-
ated with influenza virus infections.
The result of this study were potentially limited because
it was conducted in a single season and performance was
based on the circulating strains of influenza A and B
viruses during this season. Results may be different in a
seasonal outbreak when other strains of influenza predom-
inate although this is unlikely because the assay target is a
stable ribonucleoprotein, and not the neuraminidase and
hemagglutinin antigens that are responsible for the strain
heterogeneity. Although the time between the onset of the
symptoms and performance of the test can influence the
results, most tests were performed within 4 days of onset
of symptoms which is reflective of an out-patient practice.
The number of patients in the high risk population of less
than 5 years of age was low in this study, but the clinical
sensitivity and specificity for these patients was 100 %.
Test results can also be influenced by the method of
specimen collection or compliance with testing methods,
but we believe the performance of this Clinical Laboratory
Improvement Amendments-waived test is reflective of
common practice in out-patient settings.
Conclusions
In conclusion, the field performance of the Veritor Flu
A + B test was high for both pediatric and adult patients
when performed in a primary care setting. Additional
studies to demonstrate the clinical and financial impact
of this assay are warranted.
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